Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL394 Target Snapshot

HCT-116 · CELL-LINE · Homo sapiens

75,438Compounds
13,633Assays
112Approved Drugs
29,127.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats HCT-116 as ChEMBL target CHEMBL394. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
HCT-116
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL394
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether HCT-116 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHCT-116
UniProt AccessionN/A

HCT-116

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as HCT-116.

Review nameHCT-116
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

112
Approved
60
Phase III
86
Phase II
41
Phase I
Assay Mix

Activity Type Distribution

IC5027,922.0
KI1.0
EC501,201.0
KD3.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL187738 11.0 IC50 0.01 Preclinical
CHEMBL846 11.0 IC50 0.01 Approved
CHEMBL4205723 10.8 IC50 0.016 Preclinical
CHEMBL492573 10.7 IC50 0.02 Preclinical
CHEMBL441018 10.57 IC50 0.027 Preclinical
CHEMBL200899 10.52 IC50 0.03 Preclinical
CHEMBL1808822 10.35 IC50 0.045 Preclinical
CHEMBL1808826 10.35 IC50 0.045 Preclinical
CHEMBL492975 10.3 IC50 0.05 Preclinical
CHEMBL1808829 10.28 IC50 0.053 Preclinical
Distribution

pChEMBL Value Distribution

4646
5.0
3606
5.5
2822
6.0
1825
6.5
1361
7.0
888
7.5
632
8.0
359
8.5
246
9.0
52
9.5
pChEMBL
Approved Drugs

Approved Drugs

FRUQUINTINIB
CHEMBL4303214
Approved 2023
ARTESUNATE
CHEMBL361497
Approved 2020
LONAFARNIB
CHEMBL298734
Approved 2020
SELUMETINIB
CHEMBL1614701
Approved 2020
TIRBANIBULIN
CHEMBL571546
Approved 2020
TALAZOPARIB
CHEMBL3137320
Approved 2018
MIDOSTAURIN
CHEMBL608533
Approved 2017
COPANLISIB
CHEMBL3218576
Approved 2017
NIRAPARIB
CHEMBL1094636
Approved 2017
PANOBINOSTAT
CHEMBL483254
Approved 2015
BELINOSTAT
CHEMBL408513
Approved 2014
TRAMETINIB
CHEMBL2103875
Approved 2013
PONATINIB
CHEMBL1171837
Approved 2012
REGORAFENIB
CHEMBL1946170
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
CABAZITAXEL
CHEMBL1201748
Approved 2010
ROMIDEPSIN
CHEMBL343448
Approved 2009
CARFILZOMIB
CHEMBL451887
Approved 2009
OMACETAXINE MEPESUCCINATE
CHEMBL46286
Approved 2009
LAPATINIB
CHEMBL554
Approved 2007
IXABEPILONE
CHEMBL1201752
Approved 2007
VORINOSTAT
CHEMBL98
Approved 2006
ERLOTINIB
CHEMBL553
Approved 2004
TEMOPORFIN
CHEMBL500576
Approved 2001
EPIRUBICIN
CHEMBL417
Approved 1999
GEMCITABINE
CHEMBL888
Approved 1996
RALTITREXED
CHEMBL225071
Approved 1996
TOPOTECAN
CHEMBL84
Approved 1996
IRINOTECAN
CHEMBL481
Approved 1996
DOCETAXEL
CHEMBL3545252
Approved 1995
DOCETAXEL ANHYDROUS
CHEMBL92
Approved 1995
VINORELBINE
CHEMBL553025
Approved 1994
CLADRIBINE
CHEMBL1619
Approved 1993
PACLITAXEL
CHEMBL428647
Approved 1992
AMSACRINE
CHEMBL43
Approved 1987
MITOXANTRONE
CHEMBL58
Approved 1987
ETOPOSIDE
CHEMBL44657
Approved 1983
PYRVINIUM
CHEMBL1201303
Approved 1982
DIGITOXIN
CHEMBL254219
Approved 1982
NICLOSAMIDE
CHEMBL1448
Approved 1982
VERAPAMIL
CHEMBL6966
Approved 1981
MITOMYCIN
CHEMBL105
Approved 1981
DAUNORUBICIN
CHEMBL178
Approved 1979
CALCITRIOL
CHEMBL846
Approved 1978
DIGOXIN
CHEMBL1751
Approved 1975
DOXORUBICIN
CHEMBL53463
Approved 1974
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
Approved 1974
CYTARABINE
CHEMBL803
Approved 1969
VINBLASTINE
CHEMBL159
Approved 1965
VINBLASTINE SULFATE
CHEMBL378544
Approved 1965
Source · ChEMBL 36 via Core Engine